| Bioactivity | BMS905 is an orally active TLR7 and TLR8 dual inhibitor (IC50s: 0.7 and 3.2 nM respectively). BMS905 inhibits TLR7 or TLR8 induced IL-6 production in human/mouse whole blood. BMS905 can be used for research of lupus[1]. | |||||||||
| Target | TLR8 | |||||||||
| Name | BMS905 | |||||||||
| CAS | 2205846-49-5 | |||||||||
| Formula | C23H29N3 | |||||||||
| Molar Mass | 347.50 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Sreekantha RK, et al. Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8). ACS Med Chem Lett. 2022 Apr 25;13(5):812-818. |